JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v2i3.2143 jpsim.v2i3.2143 Editorial Challenges of Delivering Diabetes Care During the Covid 19 Pandemic Jones Susan E sue.jones20@nhs.net * North Tees University Hospital, Stockton on Tees, UK. Newcastle University Medical School *Correspondence: Susan E Jones (sue.jones20@nhs.net) 20 09 2021 2021 2 3 186 187 26 05 2021 13 08 2021 Copyright © 2021 The Author(s) 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 1 NHS Attend Anywhere. [ Cited July 2021] Available from: [https://england.nhs.attendanywhere.com/resourcecentre/Content/Home.htm] 2 Iyengar K, Jain VK, Vaishya R. Pitfalls in telemedicine consultations in the era of COVID 19 and how to avoid them. Diabetes & Metabolic Syndrome: Clin Res Rev. 2020 ;14(5):797-9. 3 Marsalek K, Pevtrignet S. Understanding the needs of the most clinically vulnerable to COVID-19. Unanswered questions about the shielded population. The Health Foundation. [Updated 2020, cited 2021] Available from: [https://www.health.org.uk/news-and-comment/charts-and-infographics/understanding-the-needs-and-experiences-of-those-most-clinic] 4 Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, et al. New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic. Diabetic Medicine, 2020;37(7): 1210-13. 5 The RECOVERY Trial Group. [Udated 2020, cited 2021] Available from: [https://www.recoverytrial.net/] 6 The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. NEJM 2020;doi.10.1056/NEJMoa2021436 7 Rubino F, Amiel S, Zimmet P, Alberti G, Bornstein S, Eckel R et,al. New Onset Diabetes in COVID-19. NEJM 2020;383(8):789 -90 8 Taylor S, Blau J, Rother K. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endo Metab. 2015; 100 (8):2849-52 9 Kosiborod M, Esterline R, Futado R, Ocarsson J, Gasparyan S, Koch G et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diab Endocrinol. 2021;9(9):586 -94.